Date published: 2025-11-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

DZANK1 Inhibitors

DZANK1 inhibitors are a class of chemical compounds designed to modulate the activity of the DZANK1 protein, which stands for Double Zinc Finger Ankyrin Repeat Domain-Containing Protein 1. The DZANK1 protein is characterized by its zinc finger motifs, which are known to facilitate protein-protein interactions and are frequently involved in processes related to gene expression regulation and signal transduction. Compounds in this class are designed to specifically bind to the DZANK1 protein, thereby altering its function or interaction with other cellular components. This class of inhibitors typically exhibits a structure-activity relationship that allows for precise targeting of the zinc finger and ankyrin repeat domains within DZANK1, which are critical for its function. Modulation of these domains can affect the protein's conformation, stability, and ability to interact with binding partners, leading to downstream effects on cellular processes in which DZANK1 is involved.

Chemically, DZANK1 inhibitors can vary widely in their molecular structure but often contain moieties that enhance their binding affinity and specificity to the DZANK1 protein's unique domain architecture. The structural design of these inhibitors may include aromatic rings, heterocycles, and functional groups such as amides or sulfonamides that facilitate hydrogen bonding, hydrophobic interactions, and electrostatic forces necessary for effective binding. Researchers designing these inhibitors aim to optimize their selectivity to DZANK1, minimizing off-target effects and interactions with other zinc finger or ankyrin repeat proteins. Understanding the binding kinetics, molecular docking profiles, and cellular localization of these inhibitors is key to determining their efficacy and functional impact on DZANK1 activity. Additionally, the physicochemical properties of these compounds, such as solubility, permeability, and stability, are often tailored to enhance their bioavailability and potency within a cellular context. This specificity and molecular precision make DZANK1 inhibitors a distinct chemical class with a focus on modulating a particular zinc finger and ankyrin repeat protein with precise structural features.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

(±)-JQ1

1268524-69-1sc-472932
sc-472932A
5 mg
25 mg
$226.00
$846.00
1
(0)

A BET bromodomain inhibitor, potentially affecting DZANK1 through epigenetic regulation and transcriptional control.

I-BET 151 Hydrochloride

1300031-49-5 (non HCl Salt)sc-391115
10 mg
$450.00
2
(0)

Another BET bromodomain inhibitor, which may indirectly influence DZANK1 by modulating gene expression.

MG-132 [Z-Leu- Leu-Leu-CHO]

133407-82-6sc-201270
sc-201270A
sc-201270B
5 mg
25 mg
100 mg
$56.00
$260.00
$980.00
163
(3)

A proteasome inhibitor, potentially impacting DZANK1 by affecting protein degradation pathways.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$132.00
$1064.00
115
(2)

A proteasome inhibitor, similar to MG132, could indirectly affect DZANK1 by inhibiting proteasomal protein degradation.

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$149.00
$470.00
$620.00
$1199.00
$2090.00
33
(3)

A histone deacetylase (HDAC) inhibitor, potentially influencing DZANK1 through epigenetic mechanisms.

Suberoylanilide Hydroxamic Acid

149647-78-9sc-220139
sc-220139A
100 mg
500 mg
$130.00
$270.00
37
(2)

Another HDAC inhibitor, which might affect DZANK1 activity by altering chromatin structure and gene expression.

Lithium

7439-93-2sc-252954
50 g
$214.00
(0)

Used in neurological disorders, may indirectly influence DZANK1 through pathways involved in neurodevelopment and neuroprotection.

Valproic Acid

99-66-1sc-213144
10 g
$85.00
9
(1)

A HDAC inhibitor and mood stabilizer, could affect DZANK1 indirectly through both epigenetic regulation and neuroprotective pathways.

5-Azacytidine

320-67-2sc-221003
500 mg
$280.00
4
(1)

A DNA methyltransferase inhibitor, potentially impacting DZANK1 through epigenetic mechanisms.

5-Aza-2′-Deoxycytidine

2353-33-5sc-202424
sc-202424A
sc-202424B
25 mg
100 mg
250 mg
$214.00
$316.00
$418.00
7
(1)

Similar to 5-Azacytidine, a DNA methyltransferase inhibitor, which may indirectly influence DZANK1.